Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa and IPV Vaccines Administered Separately and Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents and Adults.

Trial Profile

Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa and IPV Vaccines Administered Separately and Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents and Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; DT-poliovirus vaccine; DTaP vaccine; Poliovirus vaccine inactivated
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top